Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02118298 · ClinicalTrials.gov registry record

Allocentric Memory in MS and Resting State Functional MRI

A clinical trial of Multiple Sclerosis, sponsored by Yale University.

Completed
Registry status
120
Enrollment target
1
Study location

NCT02118298 is a study of Multiple Sclerosis that has completed, run by Yale University. The registered enrollment target is 120 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02118298, a study of Multiple Sclerosis, has completed, sponsored by Yale University.

COMPLETED
Registry status
120 participants
Enrollment target
1
Study location

Study Summary

The goals of this study are to 1. Investigate the sensitivity of allocentric visual memory when compared to more established measures of cognition in identifying cognitive difficulties among MS subjects when compared to controls. 2. Determine which cognitive test variable will be most strongly associated with self and informant reports of cognition. 3. Determine which MRI metric will be most strongly related to neuropsychological test performance 4. Determine the degree to which allocentric visual memory is related to functional connectivity on fMRI.

Conditions Studied

Study Locations (1)

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2014-04
Est. Completion 2016-04

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT02118298

The ClinicalTrials.gov registry entry for NCT02118298 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (79% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT02118298 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT02118298 about?

NCT02118298 is a clinical study titled "Allocentric Memory in MS and Resting State Functional MRI". The goals of this study are to 1. Investigate the sensitivity of allocentric visual memory when compared to more established measures of cognition in identifying cognitive difficulties among MS subjects when compared to controls. 2. Determine which cognitive test variable will be most strongly assoc...

What is the current status of trial NCT02118298?

This trial is currently completed. The enrollment target is 120 participants. The study started on 2014-04. Estimated completion is 2016-04.

What conditions does trial NCT02118298 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

Who is sponsoring clinical trial NCT02118298?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02118298 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.